McKesson publishes fiscal Q2 2027 earnings call transcript
MCK•McKesson raised its fiscal 2027 adjusted diluted EPS guidance to $45.60-$46.40 from $44.20-$45. Quarterly adjusted diluted EPS rose 18% to $11.68, and revenue increased 8% to $111 billion.
1. Quarterly results and outlook
McKesson raised its fiscal 2027 adjusted diluted EPS guidance to $45.60-$46.40 from $44.20-$45 during its second-quarter earnings call. Quarterly adjusted diluted EPS increased 18% to $11.68, while revenue rose 8% to $111 billion.
2. Acquisitions and investment
McKesson said its completed $2.25 billion acquisition of Precision Medicine Group is expected to contribute $0.10-$0.20 to adjusted diluted EPS. A proposed $1.4 billion investment for a 49% stake in Option Care Health is expected to close in the first half of calendar 2027.
